| Group | No (female) | Proportion of all 84 patients (%) | Age at epilepsy onset (years) (median (range)) | Time since seizure onset (years) (median (range)) | Right/left/bilateral affection (according to MRI) | Seizure frequency (/month) (median (range)) | No of AEDs (median (range)) |
| Whole group | 84 (28) | 100 | 42 (20–79) | 1.6 (0.0–6.0) | 25/35/24 | 6 (0–600) | 1 (0–5) |
| Four main groups | |||||||
| LE | 23 (6) | 27 | 41 (23–66) | 0.6 (0.0–5.6) | 5/5/13 | 10 (0–600) | 1 (0–5) |
| HS | 18 (8) | 21 | 38 (21–79) | 2.4 (0.6–6.0) | 8/6/4 | 6 (0–150) | 2 (0–3) |
| Tumours I°/II° | 12 (4) | 14 | 32 (20–44) | 3.0 (0.0–6.0) | 3/9/0 | 10 (3–140) | 2 (1–4) |
| Amygdala lesion | 11 (5) | 13 | 52 (23–71) | 1.0 (0.0–4.2) | 2/8/1 | 4 (1–100) | 1 (0–1) |
| Group differences: p value | Sex NS* | 0.008† | 0.011† | Bilaterality <0.001* | NS† | 0.01† | |
| Other diagnoses | |||||||
| Other | 20 (5) | 24 | 44 (28–60) | 2.0 (0.6–5.7) | 7/7/6 | 14 (1–450) | 1 (0–3) |
*χ2 test. †Kruskal–Wallis test.
AEDs, antiepileptic drugs; HS, hippocampal sclerosis (not related to LE); LE, limbic encephalitis.